Latest Research on ADHD 2026: Causes, Diagnosis, and Treatments

Abstract

Recent research indicates a significant rise in ADHD incidence during the COVID-19 pandemic, with rates increasing from 0.85 to 2.02 per 1000 person-years among Korean youth aged 6–29 years, driven by environmental stressors and SARS-CoV-2 infection as a key risk factor (Song et al., 2025). Preterm birth emerges as another causal factor, elevating ADHD diagnosis risk in adulthood despite no elevated self-reported symptoms, suggesting a predisposition to more severe presentations (Robinson et al., 2022). For diagnosis, EEG-based deep learning models integrating biomarkers like theta/beta ratio and power spectral density achieve over 90% accuracy in distinguishing ADHD from controls across ages (Khalid, 2024; Montgomery, 2024), while network analysis of pathological personality traits reveals emotional lability and impulsivity as central in full ADHD cases (Alrubaian, 2025). Treatment findings support combination pharmacotherapy with methylphenidate and atomoxetine for children unresponsive to monotherapy, showing improved symptom reduction and tolerability (Park et al., 2024), alongside behavioral parent training tailored for preschoolers and parents with ADHD, yielding Cohen's d = 1.3 for skill improvements (Dale et al., 2021; Lindström et al., 2023). Culturally adapted interventions, such as group-based parent training in Thailand and online programs in Europe, enhance parenting and reduce symptoms, though access barriers persist in low-resource settings like Brazil (Adidsuda, 2025; Bado et al., 2022; Rahali et al., 2023). Comorbidities like exercise addiction show 3.7% (95% CrI 1.9–7.9) prevalence in ADHD populations, underscoring screening needs (Violeau et al., 2025). These insights fill gaps in post-pandemic etiology and innovative diagnostics, emphasizing multimodal treatments amid rising prevalence. Implications include prioritizing early EEG screening and tailored pharmacotherapy for at-risk groups, but gaps remain in long-term outcomes and global equity. Future studies should address causality in pandemic effects and validate digital tools across diverse populations.

1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning across academic, social, and occupational domains. Affecting approximately 5–7% of children and 2–5% of adults worldwide, ADHD imposes substantial burdens, including impaired academic performance, strained family relationships, and increased risks of comorbidities such as anxiety, depression, and substance use. The COVID-19 pandemic has amplified these challenges, with disruptions like remote learning and social isolation potentially exacerbating symptoms and prompting a surge in diagnoses. Traditional views of ADHD etiology emphasize genetic and neurobiological factors, such as dopamine dysregulation and prefrontal cortex inefficiencies, but emerging evidence points to environmental influences, including prenatal insults and post-infection neuroimmune changes, as modifiable contributors.

Diagnosis remains complex, relying on subjective behavioral assessments like DSM-5 criteria, which can lead to delays or misdiagnoses, particularly in underserved populations such as racial minorities or those in low-resource settings. Treatments encompass pharmacological options, primarily stimulants like methylphenidate, and non-pharmacological approaches, including behavioral parent training and cognitive behavioral therapy (CBT), which target executive functioning and self-regulation. However, access to culturally sensitive interventions is limited, and combination therapies are underexplored for treatment-resistant cases. Recent advancements in digital tools, such as EEG-based machine learning and online parent programs, promise more objective and scalable solutions, yet their integration into clinical practice lags.

Despite these developments, the latest research from 2021–2025 has not been comprehensively synthesized to clarify evolving causal pathways, diagnostic innovations, and treatment efficacies in the post-pandemic era. This review addresses the research question: "Latest Research on ADHD 2026: Causes, Diagnosis & Treatments," by integrating findings on etiological trends, diagnostic advancements, and multimodal interventions to inform evidence-based strategies for diverse populations.

2. Methods

2.1 Search Strategy

We performed a comprehensive search across over 220 million academic papers from Semantic Scholar and OpenAlex databases. The search strategy employed hybrid semantic and keyword-based retrieval to maximize coverage.

Search queries included:

• "ADHD etiology causes risk-factors neurodevelopmental genetics environment 2021-2026"
• "ADHD diagnosis assessment screening neuropsychological-tools DSM-5 biomarkers 2021-2026"
• "ADHD medication pharmacotherapy stimulants non-stimulant atomoxetine lisdexamfetamine 2021-2026"
• "ADHD behavioral-interventions psychotherapy CBT parent-training psychosocial 2021-2026"
• "ADHD systematic-review meta-analysis causes diagnosis treatment update 2021-2026"
• "ADHD prevalence incidence epidemiology trends children adult 2021-2026"
• "ADHD digital-health biomarkers neuroimaging EEG digital-diagnosis AI machine-learning 2021-2026"

2.2 Study Selection

Initial database searching identified 280 records. After duplicate removal and relevance-based filtering, 100 records were screened against eligibility criteria. Of these, 81 papers were excluded, resulting in 19 papers included in the final synthesis.

PRISMA Flow Diagram

Eligibility criteria included:

• Year 2021-2026: Is the study published between 2021 and 2026?
• ADHD Focus: Is the main subject of the study attention-deficit/hyperactivity disorder (ADHD)?
• Human Subjects: Does the study primarily involve human participants (not animal models or simulations)?
• Relevant Domain: Does the study address ADHD causes, diagnosis, or treatment (including pharmacological and non-pharmacological interventions)?
• Recent Methods: Does the study use or describe up-to-date methods, tools, or interventions developed or applied between 2021 and 2026?
• Original Research or Systematic Review: Is the paper original research, systematic review, or meta-analysis (not a commentary/editorial)?
• Population Detail: Does the paper specify population characteristics such as age range, clinical diagnosis, or country/setting?
• Clinical Impact: Does the study discuss clinical or practical implications for ADHD diagnosis or treatment?

All included studies met the stated eligibility criteria.

2.3 Data Extraction and Synthesis

Data extraction focused on the following variables:

• Study Focus: Summarize the primary topic of the study (causes, diagnosis, or treatment of ADHD).
• Key Findings: Extract the main results or conclusions relevant to ADHD causes, diagnosis, or treatment.
• Population & Setting: Describe the population studied (age range, gender, country/setting) and key sample characteristics.
• Methodology: Summarize the study type (e.g., RCT, cohort, meta-analysis, systematic review), main methods, and duration.
• Implications & Limitations: Summarize the main clinical or research implications and note any major study limitations discussed.

Thematic analysis was employed to identify patterns and synthesize findings across studies. Evidence strength was assessed based on consistency of findings and number of supporting studies.

3. Results

3.1 Characteristics of Included Studies

The included studies span 2021–2025 and encompass diverse methodologies, including cohort designs, randomized controlled trials (RCTs), systematic reviews, meta-analyses, and qualitative assessments. Populations primarily involve children, adolescents, and young adults with ADHD or at risk, across settings from national registries in Asia to clinical trials in Europe and the Americas. Focus areas cluster around etiological trends, diagnostic innovations, and interventions, with a notable emphasis on behavioral and digital approaches in treatment.

3.2 Thematic Findings

3.2.1 Causes and Risk Factors

Evidence consistently links environmental and perinatal factors to elevated ADHD risk. The COVID-19 pandemic drove a marked increase in ADHD incidence, from 0.85 to 2.02 per 1000 person-years among youth aged 6–29 years in South Korea, exceeding model predictions and associating with SARS-CoV-2 infection as a neuroimmune trigger (Song et al., 2025). Preterm birth similarly heightens diagnosis risk in adulthood, with preterm individuals showing higher ADHD rates despite comparable self-reported symptoms to term-born peers across eight international cohorts (Robinson et al., 2022). Comorbid exercise addiction exhibits 3.7% (95% CrI 1.9–7.9) prevalence in ADHD populations and 13.9% (95% CrI 5.4–31.7) of ADHD in exercise addiction cases, potentially stemming from shared impulsivity and reward dysregulation (Violeau et al., 2025). These findings converge on external stressors amplifying neurodevelopmental vulnerabilities, though population-based cohorts provide stronger etiological inference than comorbidity meta-analyses, which rely on heterogeneous self-reports. Confidence: Moderate (consistent findings with reasonable design quality).

3.2.2 Diagnostic Innovations and Challenges

Diagnostic advancements emphasize objective biomarkers and trait profiling, contrasting with traditional subjective methods. EEG-based classification achieves over 90% accuracy in differentiating ADHD from controls by analyzing spectral features like theta/beta ratio and power spectral density, applicable across ages in computational models (Khalid, 2024; Montgomery, 2024). Network analysis of DSM-5 personality traits identifies emotional lability and impulsivity as central in full ADHD youth, callousness in subthreshold cases, and depressivity in controls, using the Personality Inventory for DSM-5 (Alrubaian, 2025). For comorbid conditions, a validated Likert scale for internet gaming disorder in Taiwanese ADHD adolescents yields AUC = 0.918, sensitivity = 0.893, and specificity = 0.826 at a cut-off ≥10 (Chang & Tzang, 2021). Neuropsychological assessments reveal racial disparities in the US, with Black and Brown children facing delayed ADHD diagnoses and higher misdiagnosis rates for oppositional defiant disorder, informed by behavioral rating scales (Malone et al., 2024). EEG methods offer higher objectivity than trait inventories, but validation varies by age and culture; preterm studies highlight diagnosis-symptom discrepancies, possibly due to register-linkage biases (Robinson et al., 2022). (Note: this study examined preterm-born adults which partially matches the question population of general ADHD populations; findings should be interpreted considering this difference.) Confidence: Moderate (generally consistent but limited contexts, populations, or mixed measures).

3.2.3 Pharmacological Treatments and Risks

Combination pharmacotherapy emerges as effective for suboptimal responders, with methylphenidate plus atomoxetine reducing ADHD severity more than monotherapy in children, alongside favorable tolerability in observational data (Park et al., 2024). Systematic reviews confirm benefits in adherence and symptom control for stimulant-intolerant cases, though one study notes no overall severity difference versus atomoxetine alone, potentially due to heterogeneous patient selection (Cheng & Boileau, 2025). Cannabis co-use with stimulants risks cognitive impairments and medication misuse, necessitating monitoring (Tripdatabase, 2025). Findings align on efficacy for resistant cases but conflict on monotherapy comparisons, attributable to retrospective designs lacking randomization; pediatric focus limits adult applicability. Confidence: Limited (sparse evidence or few supporting studies).

3.2.4 Behavioral and Digital Interventions

Parent training programs, tailored for ADHD parents or at-risk preschoolers, improve outcomes consistently. An ADHD-adapted program yields Cohen's d = 1.3 for parenting skill use, with 84% session attendance in open trials (Lindström et al., 2023; Therese et al., 2023). Family-centered profiles predict greater gains in positive parenting and symptom reduction (e.g., via cluster analysis in RCTs), with higher cohesion linked to better child behaviors (Dale et al., 2021). Culturally adapted group training in Thailand reduces symptoms in 3–5-year-olds versus education alone (Adidsuda, 2025), while online formats anticipate enhanced reinforcement strategies (Rahali et al., 2023). Digital tools address adherence barriers like executive functioning deficits (Pfiffner et al., 2022), but Brazilian needs assessments reveal access gaps due to economic and geographic constraints (Bado et al., 2022). CBT in Iranian adolescents boosts self-regulation and family dynamics, per reviews (Hashemi et al., 2025). Tailored approaches outperform standard ones, with co-creation enhancing feasibility, though small samples and lack of controls temper comparisons. Confidence: Strong (consistent findings across multiple independent studies with reasonable designs).

3.3 Summary of Evidence

4. Discussion

4.1 Principal Findings and Their Interpretation

The synthesis reveals a post-pandemic surge in ADHD incidence, with rates doubling to 2.02 per 1000 person-years, likely due to neuroimmune alterations from SARS-CoV-2 and stressors like online learning disrupting dopamine pathways central to attention regulation (Song et al., 2025). This temporal association, exceeding predictive models, suggests environmental triggers amplify genetic vulnerabilities, a pattern only evident when cohort data align with comorbidity meta-analyses showing 3.7% exercise addiction overlap via shared impulsivity circuits (Violeau et al., 2025). Preterm birth's diagnostic elevation without symptom self-reports implies subclinical neurodevelopmental insults, such as white matter disruptions, manifesting as severe phenotypes requiring intervention (Robinson et al., 2022). High confidence stems from consistent, population-based designs, but tentative conclusions on mechanisms arise from absent direct neuroimaging in these studies, highlighting a gap in linking infection to prefrontal inefficiencies.

Diagnostic innovations like EEG models (>90% accuracy via theta/beta integration) offer objective alternatives to DSM-5 subjectivity, potentially by capturing real-time neural dysregulation missed in rating scales (Montgomery, 2024; Khalid, 2024). Trait networks pinpointing emotional lability in ADHD further refine severity profiling, with moderate confidence from cross-sectional consistency but limited by self-report reliance (Alrubaian, 2025). Pharmacologically, combination therapies' symptom benefits reflect synergistic noradrenergic-dopaminergic modulation for resistant cases, though mixed monotherapy comparisons indicate variable response thresholds (Cheng & Boileau, 2025; Park et al., 2024). Behavioral interventions' robustness (Cohen's d = 1.3) underscores family dynamics' role in sustaining executive function gains, with digital adaptations addressing adherence via cognitive prompts (Lindström et al., 2023; Pfiffner et al., 2022). Collectively, these patterns advance understanding by revealing multimodal convergence—etiology informs targeted diagnostics, enhancing treatment personalization—beyond isolated study insights, with strongest evidence for behavioral efficacy due to RCT support.

4.2 Comparison with Existing Literature and Resolution of Contradictions

Findings align with prior literature on ADHD's multifactorial etiology, where genetic models (e.g., heritability ~70%) are augmented by environmental hits like prematurity, consistent with register studies showing preterm risks via hypoxic-ischemic pathways (Robinson et al., 2022). Pandemic-driven incidence echoes pre-2020 trends of rising diagnoses but extends them mechanistically, as neuroimmune inflammation may parallel prenatal exposures in altering reward processing, reinforcing robustness against isolated cohort variability. Comorbidity prevalence exceeds general population estimates, supporting impulsivity as a transdiagnostic bridge, though meta-analytic heterogeneity (CrI widths >5%) reflects diagnostic inconsistencies in prior work.

Contradictions appear in pharmacological outcomes, where one review finds no severity edge for combinations over atomoxetine monotherapy, contrasting others' benefits for resistant youth (Cheng & Boileau, 2025; Park et al., 2024). This may stem from population heterogeneity—observational pediatric data capture real-world resistance better than aggregated adult-inclusive reviews—coupled with unadjusted confounders like adherence metrics, introducing selection bias in non-randomized designs. Null self-reports in preterm adults versus diagnostic hikes (Robinson et al., 2022) likely reflect survivor bias, where milder cases underreport, unlike objective registers; no data substantiates reverse causality, but methodological evolution from self-reports to linked registries resolves prior inconsistencies by prioritizing clinical validation. Publication bias risks positive diagnostic accuracies (>90%), as negative EEG trials may go unreported, yet behavioral intervention consistency across cultures mitigates this, aligning with global CBT meta-analyses on self-regulation gains (Hashemi et al., 2025). Recent digital methods enhance precision over older rating scales, bolstering reliability in diverse settings.

4.3 Practical Implications

For youth in high-stress environments like post-pandemic South Korea, where incidence doubled, clinicians should prioritize SARS-CoV-2 history in risk stratification, recommending early neurological evaluations for infected individuals to preempt severe trajectories (Song et al., 2025). Preterm adults warrant proactive screening despite low self-reports, as elevated diagnosis risks signal hidden vulnerabilities best addressed through integrated primary care in international cohorts (Robinson et al., 2022). Racial minorities in the US, facing diagnostic delays, benefit from culturally informed neuropsychological assessments to curb oppositional misdiagnoses, particularly in school settings for Black and Brown children (Malone et al., 2024).

In treatment, children unresponsive to stimulants should transition to methylphenidate-atomoxetine combinations under monitored protocols, given tolerability advantages in pediatric clinics (Park et al., 2024). Parents with ADHD gain from tailored programs like IPSA, implementable in community centers to boost skills (Cohen's d = 1.3) and family cohesion (Lindström et al., 2023). Digital tools suit remote access in low-resource areas like Brazil, targeting adherence barriers for school-age families (Bado et al., 2022; Pfiffner et al., 2022). Cannabis-using patients require substance-integrated monitoring to avert cognitive risks (Tripdatabase, 2025). Public health efforts should scale culturally adapted CBT in regions like Iran for adolescents, enhancing emotional regulation amid academic pressures (Hashemi et al., 2025). These apply to clinical subgroups (e.g., youth, parents) partially matching general populations; evidence gaps preclude broad adult recommendations.

4.4 Strengths and Limitations

Strengths include a comprehensive search yielding diverse, recent studies (2021–2025) across global contexts, enabling thematic synthesis of evolving ADHD research with prioritized extracted data for structured insights. The focus on human-centric, impactful findings ensures clinical relevance.

Limitations of included studies encompass observational biases in etiological cohorts (e.g., claims data variability (Song et al., 2025)), small samples in trials (e.g., n=16 for feasibility (Lindström et al., 2023)), and unspecified demographics in diagnostic models, restricting generalizability. Many lack long-term follow-up, and cultural adaptations are uneven.

This review's limitations involve abstract-based screening potentially missing nuances, extraction reliance on provided fields without full texts, and no formal risk-of-bias tool, though thematic grouping mitigates inconsistencies.

5. Gaps and Future Directions

Synthesis highlights gaps in mechanistic evidence, such as direct neuroimaging linking SARS-CoV-2 neuroimmunity to ADHD onset, absent across studies relying on temporal associations (Song et al., 2025). Preterm findings lack causal pathways beyond registers, with no replication in non-Western adults (Robinson et al., 2022). Diagnostic EEG models (>90% accuracy) require validation in diverse ethnic groups, as US minority disparities remain underexplored beyond trends (Malone et al., 2024; Montgomery, 2024). Pharmacological reviews show mixed monotherapy comparisons due to heterogeneous resistance definitions, needing standardized metrics (Cheng & Boileau, 2025). Behavioral interventions overlook long-term child outcomes, with Brazilian access barriers unaddressed by trials (Bado et al., 2022).

Future RCTs should target general ADHD populations (beyond preterm or Asian youth) using personal EEG for causality. Methodological advances like multi-site, harmonized pharmacotherapy protocols with biomarkers would clarify combinations. Underrepresented low-income, adult, and Middle Eastern contexts demand culturally validated CBT and digital tools to bridge equity gaps.

6. Conclusion

The latest research affirms environmental factors like the COVID-19 pandemic and preterm birth as key ADHD causes, with incidence rising to 2.02 per 1000 person-years in South Korean youth and heightened adult diagnosis risks in preterm cohorts, alongside 3.7% (95% CrI 1.9–7.9) exercise addiction comorbidity (Robinson et al., 2022; Song et al., 2025; Violeau et al., 2025). Diagnosis benefits from EEG innovations achieving >90% accuracy and trait networks identifying emotional lability as central, particularly addressing US minority disparities (Alrubaian, 2025; Malone et al., 2024; Montgomery, 2024). Treatments favor methylphenidate-atomoxetine combinations for pediatric resistance and tailored parent training yielding Cohen's d = 1.3 skill gains, with digital enhancements improving access (Park et al., 2024; Lindström et al., 2023; Pfiffner et al., 2022). These conclusions draw from youth and clinical subgroups partially matching broader populations, emphasizing pediatric and Asian/European contexts while noting adult and global underrepresentation.

Uncertainties persist in causal mechanisms, such as infection-induced neuroinflammation, demanding mechanistic studies to refine prevention. This matters for public health by guiding post-pandemic screening to curb rising prevalence, clinically by personalizing interventions to reduce family burdens, and policy-wise by advocating equitable access in underserved areas—potentially transforming ADHD management if integrated into routine care, motivating rigorous trials for lasting impact.

References

Adidsuda, F. (2025). Parent training interventions for preschool children at risk of ADHD: A randomized controlled trial. Figshare. https://doi.org/10.6084/m9.figshare.30866471.v1

Alrubaian, A. (2025). Comparing DSM-5 pathological personality traits in youths with ADHD, subthreshold ADHD, and healthy controls using the Personality Inventory for DSM-5 (PID-5): A network analysis study. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-025-07079-1

Bado, P., Costa, R. da, Bernardes, C., Tripp, G., Mattos, P., & Furukawa, E. (2022). Needs assessment for behavioral parent training for ADHD in Brazil. https://doi.org/10.31234/osf.io/mnc95

Chang, Y., & Tzang, R. (2021). Proposing and validating the diagnosis scale for internet gaming disorder in Taiwanese ADHD adolescents: Likert scale method based on the DSM-5. International Journal of Environmental Research and Public Health, 18, 1492. https://doi.org/10.3390/ijerph18041492

Cheng, T., & Boileau, A. J. (2025). Effectiveness of atomoxetine and stimulant combination in attention-deficit/hyperactivity disorder (ADHD) treatment: A systematic review. Cureus, 17, e79378. https://doi.org/10.7759/cureus.79378

Dale, C., Parent, J., Forehand, R., DiMarzio, K., Sonuga-Barke, E., Long, N. J., & Abikoff, H. (2021). Behavioral parent training for preschool ADHD: Family-centered profiles predict changes in parenting and child outcomes. Journal of Clinical Child & Adolescent Psychology, 51, 726–739. https://doi.org/10.1080/15374416.2020.1867987

Hashemi, S. S., Zulkefly, N. S., Sulaiman, W. S. W., Kadir, H. B., Angali, K. A., & Moosavi, A. (2025). Expanded literature review on ADHD and cognitive behavioral therapy (CBT) in the Iranian context. Psikoeduko Jurnal Psikologi Edukasi Dan Konseling, 5, 21–28. https://doi.org/10.17509/psikoeduko.v5i1.80308

Khalid, A. (2024). EEG-based classification of ADHD: A promising digital innovation for early diagnosis. Qatar University QSpace.

Lindström, T., Buddgård, S., Westholm, L., Forster, M. O., Bölte, S., & Hirvikoski, T. (2023). Parent training tailored to parents with ADHD: Development of the Improving Parenting Skills Adult ADHD (IPSA) program. Journal of Attention Disorders, 28, 531–541. https://doi.org/10.1177/10870547231217090

Malone, L. S., Sloan-Peña, G., Rader, K., & Flagg, A. (2024). A-69 The use of neuropsychological assessments in the diagnosis of ADHD among racial and ethnic minorities in the US. Archives of Clinical Neuropsychology, 39, 1007. https://doi.org/10.1093/arclin/acae067.083

Montgomery, R. M. (2024). Deep learning for ADHD diagnosis: Integrating diverse EEG biomarkers for enhanced predictive accuracy. Preprints.org. https://doi.org/10.20944/preprints202407.2416.v1

Park, H. N., Kong, N., Kim, H., Kim, Y., Jung, S., & Lee, H. (2024). Effectiveness and tolerability of combination pharmacotherapy with stimulant and non-stimulant in children with attention deficit hyperactivity disorder. Journal of Korean Academy of Child and Adolescent Psychiatry, 35, 82–89. https://doi.org/10.5765/jkacap.230048

Pfiffner, L. J., Dvorsky, M. R., Hawkey, E., Chung, S., Haack, L. M., & Owens, E. B. (2022). Improving adherence to behavioral parent training for ADHD using digital health tools. Journal of Psychiatry and Brain Science, 7. https://doi.org/10.20900/jpbs.20220005

Rahali, M., Fongaro, E., Franc, N., Nesensohn, J., Purper-Ouakil, D., & Kerbage, H. (2023). Expected changes in parenting after an online parent training for ADHD. L'Encéphale, 50, 59–67. https://doi.org/10.1016/j.encep.2023.01.007

Robinson, R., Girchenko, P., Pulakka, A., Heinonen, K., Lähdepuro, A., Lahti-Pulkkinen, M., Hovi, P., Tikanmäki, M., Bartmann, P., Lano, A., Doyle, L. W., Anderson, P. J., Cheong, J. L. Y., Darlow, B. A., Woodward, L. J., Horwood, L. J., Indredavik, M. S., Evensen, K. A. I., Marlow, N., … Räikkönen, K. (2022). ADHD symptoms and diagnosis in adult preterms: Systematic review, IPD meta-analysis, and register-linkage study. Pediatric Research, 93, 1399–1409. https://doi.org/10.1038/s41390-021-01929-1

Song, J., Park, S. J., Jeong, S., Chun, A. Y., & Park, S. M. (2025). Increasing incidence of ADHD among children, adolescents and young adults: COVID-19 pandemic-driven trend in Korea (2012–2023). BMJ Mental Health, 28, e301662. https://doi.org/10.1136/bmjment-2025-301662

Therese, L., Sofia, B., Lena, W., Martin, F., Sven, B., & Tatja, H. (2023). Parent training tailored to parents with ADHD: Development of the Improving Parenting Skills Adult ADHD (IPSA) program. Sage Journals Data. https://doi.org/10.25384/sage.c.7000670

Tripdatabase. (2025). What are the risks of combining cannabis with stimulant medication for ADHD? Zenodo. https://doi.org/10.5281/zenodo.17801679

Violeau, L., Faugère, M., Rahmati, M., Rozier, P.-E., Smith, L., Yon, D. K., López-Gil, J. F., Fonséca, D. D., Lançon, C., & Boyer, L. (2025). ADHD and exercise addiction: A systematic review and prevalence meta-analysis. SPIRE - Sciences Po Institutional Repository. https://hal.science/hal-05477170v1